 |
History |
 |
|
| |
|
|
 |
|
|
Shanghai Sunway Biotech Co.,Ltd. is a leading Chinese
biopharmaceutical company that develops, manufactures
and commercializes cancer biotherapeutics based on its
oncolytic viral technology. The registered capital of
the company is $ 15 M. Shanghai Sunway Biotech Co. Ltd
has been established on the 29th of December 1995 with
the goal of developing and creating innovative therapies
for unmet medical needs in the treatment of cancer and
other life-threatening diseases. In 1999, after a second
private placement, it became a Joint Venture company
between Mergen Biotech (73.26%), S. I. Pharmaceutical
holdings ltd (8.14%) and Shanghai Alliance Investment
(18.6%). Shanghai Sunway Biotech’s headquarter is in
Shanghai’s Pudong District.
 |
| |
 |
|
The company is the main developer of the H100 technology
and genetically
engineered adenoviruses for cancer treatments.
It has successfully developed drugs to treat cancer
such as H101,
H102,
and H103.It
has demonstrated an excellent capability in conforming
to international business standards and respects IP
protection. New Sunway Biotech’s drugs have obtained
Chinese patents. H102 has
an international patent; it is indicated to treat liver
cancer, and is in pre-clinical development. H103
is just in the phase I of the clinical trial and is
indicated to treat local site with systemic
anti-tumor effect. H101
is the first product of the H100 series. It is a genetically
engineered adenovirus. The H101 can replicate
itself in the tumor
cells. These replications lead to the tumor
cell lyses and so destroy the tumor. In most tumor
cells (more than 50%), the P53
pathway is deficient, and that is why the adenovirus
can replicate itself in it. That is why the H101
replication
and the lyses are impossible in a normal cell. H101
will kill only the tumor cells, not/never the normal
ones. The H101 does not have
the side-effects of chemotherapy like the extreme tiredness,
the loss of the hair, nauseas…H101
Phase I, II, III clinical trials have demonstrated good
effects and safety for the human body in the treatment
of head
and neck cancer, lung and sarcoma.
See more on the Research
and Development section |
| |
 |
|
Sunway Biotech Co.,Ltd has a genetically engineered
protein drug rhG-CSF
(recombinant human granulate-colony
stimulating factor) on the market. Its main
indication is treating neutropenia
caused by chemotherapy
for cancer patients. The development of rhG-CSF
has been supported by various governmental grants and
awards.
Get more information about Sunways’s products in the
Products section. |
| |
 |
|
Sunway Biotech Co.,Ltd is a leading biotech company
in China. Its strategic development is to bring more
new drugs to the market and to develop its competitive
capacities in order to set up business not solely in
China but all over the world. Shanghai Sunway Biotech’s
development plan is focused on biological medicine therapy.
Sunway Biotech Co. Ltd currently has 12 patent applications
in process for the products of H100 series in China,
in the USA, and in and other countries.
(see Research
and Development) |
| |
 |
|
As one of the most important high-tech companies in
Shanghai, Sunway Biotech Co. Ltd has always gotten strong
support from government at all levels. The Administration
in charge of the development of high-tech enterprises
of Pudong District certified that Sunway Biotech Co.,Ltd
respects its rules. Sungran
(rhG-CSF) has already been successfully launched
into the market place. H101,
H102
and H103
are still in development. SunGran (rhG-CSF), H101, H103
belong to the national “863 High-Tech Program”. Sungran
has won the High-Tech Achievement Award from Shanghai
Municipal Government in 1998. In 2000, Sunway got the
Ministry of Science and Technology funding for the H101.
In 2004, Sunway won the High-tech Award from the city
of Shanghai. |
| |
|
|
Mr. Fu Hui, Vice President
Mr. Fu Hui earned his master's and bachelor's degree at Zhe Jiang University in the Dept. of Chemical Industry. He was responsible for the project 'Small scale process study of one-step fermentation of Vitamin C', and finished one of the China National Hi-tech project (863 project) 'Industrialization of G-CSF', and established the sales team in the company. He has over 10 years' managerial experience in development, industrialization and sale of biotech medicine.
Dr. Liang Min, PhD, Vice President
Dr.Liang earned his doctorate degree at Fudan University, and his master's degree at Institute of Virology, CAPM, and his Bachelor's degree at Wu Han University. He started his research and development works of biotech medicine for cancer therapy since early 1990's, then focused on the field of oncolytic virus, resulted the leading product H101(Oncorine) which has been launched to Chinese market after 8 years' development in 2006. Dr. Liang is the member of ASGT( American Society of Gene Therapy), he is also the principal investigator of a series grants from China National Hi-tech project (863 project). Dr. Liang is the inventor of a series patents for cancer gene therapy.
| |
